ABSTRACT
SAŽETAK

Interesovanje za kliničku primenu kompleksa prelaznih metala kao hemioterapijskih lekova započeto je otkrićem cisplatine. Uprkos izvanrednom kliničkom uspehu, lečenje cisplatinom je ograničeno zbog njene rezistencije i neželjenih efekata. Tokom poslednjih 40 godina sintetisan je veliki broj kompleksa prelaznih metala i ispitan in vitro i in vivo sa ciljem uvođenja metalofarmaceutika koji bi imao manju toksič-nost i istu ili veću potentnost. Mi smo poredili kardiotoksičnost dva kompleksa platine, jedan ligand i so potrebnu za početak sinteze kompleksa, koristeći eksperimentalni model izolova
. Cisplatin is one of the most effective chemotherapeutic agents for the treatment of various cancers, such as lung, bladder, neck, ovarian, and testicular (3). It has a potent cytotoxic effect due to its ability to cross-link DNA through a covalent coordinate bond to the N7 atoms of guanine and adenine. This molecular mechanism prevents replication and transcription of DNA and finally leads to apoptosis and cell death (4) . Other targets of cisplatin are glutathione and metallothioneins, to which binding has been associated with the development of resistance and toxicity (5) . Accordingly, the clinical use of cisplatin is severely limited, especially by dose-dependent side effects, such as nephro-, oto-, neuro-, hepato-, and cardiotoxicity (6, 7) . Over the past decades, medicinal chemists have been devoted to the development of a large number of novel platinum complexes with less toxicity and more antitumour success (8, 9) .
Many preclinical and clinical researchers have suggested that chronic cisplatin therapy is associated with severe side effect such as cardiotoxicity (10, 11) . Cardiotoxicity may be an early or late complication after treatment with cisplatin. Acute manifestations are accompanied with electrocardiographic changes and arrhythmias, while late complications are primarily associated with the development of cardiomiopathy and congestive heart failure (12) (13) (14) . Experimental evidence supports the hypothesis that cisplatin and its analogues promote cardiotoxicity through the formation of reactive oxygen species (ROS), such as superoxide anion radical (O 2 -. ), hydrogen peroxide (H 2 O 2 ), Thiobarbituric Acid Reactive Substances (TBARS), and nitric oxide (NO) (15, 16) . Numerous studies reported that cisplatin has a potential to induce oxidative damage in heart tissue by causing peroxidation of the cell membrane and dysfunction of mitochondria (17, 18) .
The present study was performed in order to assess the cardiotoxicity of cisplatin and its analogue, Pt (II) DACHCl 2 (dichloro(1,2-diaminocyclohexane)platinum (II)), in isolated rat heart by means of oxidative stress markers in the coronary venous effluent. 
MATERIALS AND METHODS
Preparation of isolated rat hearts
Biochemical assays
Samples of coronary venous effluent were collected at the end of the period of perfusion with each of the tested compounds (30, 60, 90, 120 minutes).
Superoxide determination
Superoxide anion radical (O 2 .-) levels were measured in the coronary venous effluent by nitro blue tetrazolium (NBT) in TRIS buffer at a wavelength of 530 nm. KrebsHenseleit solution was used as a blank probe (19) .
Hydrogen peroxide determination
Hydrogen peroxide (H 2 O 2 ) levels were determined by measuring the oxidation of phenol red in a reaction catalysed by horseradish peroxidase (HRPO). The level of H 2 O 2 was measured at 610 nm (20).
Nitrite determination
The nitrite level (NO 2 -) was measured and used as an index of nitric oxide (NO) production using Griess's reagent. A total of 0,5 ml of perfusate was precipitated with 200 μl of 30% sulphosalicylic acid, vortexed for 30 min and centrifuged at 3000 g. Equal volumes of the supernatant and Griess's reagent, containing 1% sulphanilamide in 5% phosphoric acid/0,1% naphtalene ethylenediamine dihydrochloride, were added and incubated for 10 min in the dark and measured at 543 nm. The nitrite levels were calculated using sodium nitrite as a standard (21) .
Determination of TBARS (Index of lipid peroxidation)
The degree of lipid peroxidation in the coronary venous effluent was estimated by TBARS (Thiobarbituric Acid Reactive Substances) using 1% thiobarbituric acid (TBA) in 0,05 sodium hydroxide (NaOH), incubated with coronary effluent at 100°C for 15 minutes and measured at 530 nm. Krebs-Henseleit solution was used as a blank probe (22 4 ], DACH and substances necessary for the preparation of Krebs-Henseleit buffer were purchased from the company Sigma-Aldrich GmbH, Germany.
Statistical Analysis
Experimental data were expressed as the arithmetic mean value (X) ± standard deviation (SD). Linear regression on logarithmically transformed data was used to determine the concentration-response relationship. This was calculated according to the method of least squares. The effect of different concentrations of experimental substances was expressed as a percentage of the maximal response. Analysis of variance was used to test significance of the linear regression with p values lower than 0.05 considered statistically significant. For all experimental substances, we calculated the EC 50 , the concentration eliciting 50% of the maximum response.
RESULTS
The results are summarized in Tables 1, 2 
DISCUSSION
The mechanisms of the anticancer effects of cisplatin are relatively well-known, but the cellular and molecular mechanisms involved in its cardiotoxicity are still not clear (24) . Cardiotoxicity is a severe side effect that can occur during cisplatin treatment and is a limiting factor of cisplatin use in chemotherapy (25, 26) . The best studied antitumour drugs with cardiotoxic effects are anthracyclines; however, in recent years, much attention has been paid to the mechanisms of cisplatin-induced cardiotoxicity. Many preclinical and clinical studies indicate that the use of anthracyclines is associated with myocardial damage, which is initiated by the formation of oxidative free radicals. Sawyer et al. (27) showed that apoptotic cells could be found in rat cardiomyocytes upon exposure to doxorubicin. Additionally, several investigations have shown the role of mitochondrial damage in a few models of nephroand ototoxicity induced after cisplatin administration (28, 29) . Mitochondria have a central role in myocardial tissue homeostasis, since cardiomyocytes are cells with high energy metabolism. Cardiac myocytes can accumulate a large amount of cisplatin and establish enhanced mtDNA damage. Thus, impairment in mitochondrial function leads to apoptosis of myocytes and endothelial cells and consequent cardiac dysfunction. Mitochondrial dysfunction can develop via various mechanisms, such as the loss of mitochondrial membrane potential, depletion of mitochondrial antioxidant enzymes, and increase in oxidative and nitrosative stress, which can induce cell death (30) . The increase of oxidative stress and apoptosis in rat liver after cisplatin treatment (31) and overproduction of ROS in rat heart tissue (32) may lead to cardiovascular complications.
Hence, excessive production of ROS (superoxide anion radical, hydrogen peroxide, thiobarbituric reactive substances, and nitric oxide), in addition to the impairment of the defence system of antioxidant enzymes (superoxide dismutase, catalase, and glutathione peroxidase), contributes to oxidative stress damage of the heart tissue (33). The levels of antioxidants, such as glutathione (GSH), are decreased significantly during cisplatin therapy with a high cumulative dose (34) .
Cisplatin causes severe cardiotoxic effects that can impair the quality of life thus a Pt(II)DACHCl2 complex was synthesized and tested for cardiotoxicity in the isolated rat heart. Platinum (II) complexes with 1,2-diaminocyclohexane (DACH) as a ligand display high cytotoxic activity in tumours with a primary resistance to cisplatin, as well as lower nephro-and myelotoxicity (35) . Success of oxaliplatin, which incorporates the 1R,2R-DACH ligand as platinum (II) complex, raised research interest over the past few decades for platinum-DACH complexes. Platinum (II) analogues have a strong potential for binding to sulphur donor groups, such as glutathione and metallothioneins. Consequently, before this complex reaches the DNA of the cancer cells, it can interact with many compounds, resulting in its inactivation and side effects (26) .
In our study, isolated rat hearts were perfused with two platinum complexes in divergent concentrations as follows: 10 The data obtained in our study showed that the Pt (II) DACHCl 2 complex induced higher levels of hydrogen peroxide production (Table 2 ) through the whole range of applied doses (10 -8 -10 -4 M), which is in contrast to the CDDP results. Numerous effects of oxidative stress are observed in many diseases and are also implicated in the toxicity induced by anticancer agents such as cisplatin. There is in vivo and in vitro evidence that cisplatin induces oxidative stress, which is involved in renal damage and severe nephrotoxicity. This is confirmed by the increasing levels of O 2 -. , H 2 O 2 and hydroxyl radicals, as well as by the depletion of the antioxidants GSH-peroxidase and GSH-reductase (17) .
The present study determined the nitrite level (NO 2 -) as an index of nitric oxide (NO) production (Table 3) . It was shown that formation of NO is higher at lower doses of each complex (10 -8 -10 -7 M) and is lower at higher doses (10 -6 -10 -4 M). Table 3 .The effects of CDDP, Pt (II) DACHCl 2, DACH, K 2 PtCl 4 perfusion on NO Demkow and coauthors (37) observed a significant increase of NO production in lung cancer patients after cisplatin administration. In the presence of a superoxide anion radical, nitric oxide forms peroxynitrite, which is more reactive and toxic, and has a potential for apoptosis of cells such as cardiomyocytes (38) . In accordance with these results, Zhou et al. (39) reported significant elevation of serum NO after chemotherapy in patients with lung cancer. Chirino et al. (17) also showed that high production of peroxynitrite plays a role in the pathogenesis of nephrotoxicity after cisplatin application. Peroxynitrite can induce cell damage by developing lipid peroxidation, causing DNA damage and mitochondrial dysfunction. In contrast, Colakogullari and coworkers (40) did not observe high concentrations of NO as an early effect of cisplatin therapy. This variation can be attributed to different study protocols.
In our research, TBARS was measured as an index of lipid peroxidation, and it is observed that levels of lipid peroxidation were higher at lower doses of cisplatin (10 (Table 4) . (10 -4 M), which is in contrast to cisplatin. Cardiotoxicity associated with cisplatin therapy could also be the consequence of increased lipid peroxidation in myocardial cells that resulted in irreversible modification of cell functions. Free radicals can cause serious damage to tissue, reacting with membrane lipids, proteins and nucleic acids (41) . After cisplatin is distributed to a cell, it is aquated into a highly reactive form, which can react with GSH and metallothioneins. Depletion of GSH levels and antioxidants results in the accumulation of ROS (42, 43) .
The current study compared the Pt (II) DACHCl 2 complex to CDDP for their ability to develop cardiotoxicity by the production of free radicals. Over the complete dosage range tested, neither complex produced a statistically significant elevation of ROS or induced evidently cardiotoxic effects. Data presented in this research could be useful for future investigations of platinum-based chemotherapeutic agents. These results suggest that further elucidation of platinum (II) analogue-induced cardiotoxicity should add significantly to our understanding of this phenomenon and the role of platinum complexes with DACH ligands in anticancer treatment.
